We are live on
!
Find out more
CA
CHI Advisors Portfolio holdings
AUM
$252M
1-Year Est. Return
56.99%
This Fund
S&P 500
This Quarter
Est. Return
+13.1%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$377M
AUM Growth
+$1.24M
(+0.33%)
Cap. Flow
-$2.89M
Cap. Flow
% of AUM
-0.77%
Top 10 Holdings %
Top 10 Hldgs %
89.68%
Holding
27
New
4
Increased
7
Reduced
9
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSVT
2seventy bio
TSVT
|
+$5.97M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$3.22M |
| 3 |
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
|
+$2.98M |
| 4 |
Keros Therapeutics
KROS
|
+$2.32M |
| 5 |
RPTX
Repare Therapeutics
RPTX
|
+$2.27M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KZR
Kezar Life Sciences
KZR
|
+$6.94M |
| 2 |
Pliant Therapeutics
PLRX
|
+$4.78M |
| 3 |
Larimar Therapeutics
LRMR
|
+$3.8M |
| 4 |
INZY
Inozyme Pharma
INZY
|
+$2.28M |
| 5 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
+$1.96M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.97% |
| 2 | Miscellaneous | 0.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
CALL
Pliant Therapeutics
PLRX
$71.2M
| – | – |
-30,000
| Closed | -$29.3K |
|
|
GTHX
27
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – |
-333,945
| Closed | -$1.81M |
|
Similar funds
SC
T
W
RBGI
TOGEPT
IAM
RCGI
AEPLI
CHI Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, CHI Advisors held 27 positions worth $377M, up 0.33% from $375M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
CHI Advisors's Q1 2023 filing shows 4 new, 7 increased, 9 reduced and 3 closed positions. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 135,000 shares worth $3.13M. The largest sale was Kezar Life Sciences, an estimated $6.94M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.
- CHI Advisors's largest Q1 2023 buy was Chinook Therapeutics, Inc. Common Stock: 135,000 shares worth $3.13M.
- CHI Advisors added most to 2seventy bio in Q1 2023, an estimated $5.97M increase.
- CHI Advisors's biggest Q1 2023 reduction was Kezar Life Sciences, cutting an estimated $6.94M.
- CHI Advisors fully exited G1 Therapeutics, Inc. Common Stock in Q1 2023, selling an estimated $1.81M.
- CHI Advisors's ten largest holdings make up 90% of its $377M portfolio in Q1 2023.
- CHI Advisors opened 4 new positions and closed 3 in Q1 2023.
- CHI Advisors's portfolio value rose 0.33% quarter-over-quarter to $377M.
Based on CHI Advisors's 13F filing for Q1 2023, filed 11 May 2023.